Table 1.
EFV conceptions and regimen substitutions.
| EFV conceptions (n = 56) | n (%) |
|---|---|
| Pregnancies carried forward on EFV | 9 (16%) |
| Women receiving regimen substitutions | 25 (45%) |
| Pregnancies miscarried prior to regimen substitution | 3 (5%) |
| Pregnancies terminated | 19 (34%) |
|
| |
| Extent of EFV exposure during pregnancy | Median (IQR) |
|
| |
| Time from EFV conception to detection (n = 56), weeks | 4 [1–6] |
| Time from pregnancy detection to regimen change (n = 25), days | 1 [1–28] |
| Total time of first trimester EFV exposure in pregnancies carried to term (n = 34), weeks | 8 [5–13] |
|
| |
| Fertility-related regimen substitutions to NVP or LPV/r† | |
|
| |
| Clinical characteristics of women changed from EFV to NVP, n = 38 (67%) | Median (IQR) |
|
| |
| CD4 count, cells/μL | 257 (185–412) |
| Log10 Viral load, copies/mL | 1.7 (1.7–2.1) |
| Alanine aminotransferase (ALT) levels, U/L | 26 (21–39) |
|
| |
| Clinical characteristics of women changed from EFV to Lopinavir/Ritonavir, n = 19 (33%) | Median (IQR) |
|
| |
| CD4 count, cells/μL | 573 (333–684) |
| Log10 Viral load, copies/mL | 1.7 (1.7-1.7) |
| Alanine aminotransferase (ALT) levels, U/L | 25 (19–44) |
†Includes regimen changes for EFV conceptions and preventive changes for women trying to conceive.
EFV: Efavirenz; NVP: Nevirapine; LPV/r: Lopinavir/ritonavir.